![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
EFFECT OF FALDAPREVIR ON RALTEGRAVIR PHARMACOKINETICS IN HEALTHY VOLUNTEERS
|
|
|
Reported by Jules Levin
CROI 201 March 3-6 Boston, MA
David Joseph1, Peter Rose2, Natalja Strelkowa2, Armin Schultz3, Jeanette Garcia1, Mabrouk Elgadi4, Anne-Marie Quinson1, Fenglei Huang1
1Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; 2Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; 3CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany; 4Boehringer Ingelheim Ltd, Burlington, ON, Canada
![CROI1.gif](../images/032114/032114-4/032114-3/CROI1.gif)
![CROI2.gif](../images/032114/032114-4/032114-3/CROI2.gif)
![CROI3.gif](../images/032114/032114-4/032114-3/CROI3.gif)
![CROI4.gif](../images/032114/032114-4/032114-3/CROI4.gif)
![CROI5.gif](../images/032114/032114-4/032114-3/CROI5.gif)
![CROI6.gif](../images/032114/032114-4/032114-3/CROI6.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|